Paper No
Date filed: March 24, 2017

#### Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas NKallas@fchs.com ZortressAfinitorIPR@fchs.com (212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

# WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED, Petitioner,

v.

## NOVARTIS AG, Patent Owner.

Case IPR2017-01078 Patent 9,006,224

# PATENT OWNER'S MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(2)



### REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis AG ("Novartis" or "Patent Owner") owns U.S. Patent No. 9,006,224 ("the '224 Patent"). Novartis is the real party-in-interest in IPR2017-01078.

### RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The '224 Patent has been asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-474-RGA (D. Del.); and (2) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-475-RGA (D. Del.) (order dismissing proceeding filed October 15, 2015).

The '224 Patent is also the subject of the following Petitions for *Inter Partes* Review: Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-01461 (P.T.A.B.) (institution granted February 15, 2017); Novartis AG v. Roxane Labs., Inc., *Inter Partes* Review No. 2016-01461 (P.T.A.B.) (institution denied February 13, 2017); Novartis AG v. Argentum Pharm. LLC, *Inter Partes* Review No. 2017-01063 (P.T.A.B.) (petition filed March 10, 2017, institution decision pending).

## IDENTIFICATION OF LEAD AND BACK-UP COUNSEL PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel and Laura K. Fishwick (Reg. No. 69,907) as back-up counsel.



A power of attorney from Novartis is being submitted with this Notice.

## SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

Novartis may be served electronically using the following e-mail address:

ZortressAfinitorIPR@fchs.com

Novartis may be served by postal mailing, hand-delivery, telephone or

facsimile as follows:

Nicholas N. Kallas Fitzpatrick, Cella, Harper & Scinto 1290 Avenue of the Americas New York, NY 10104 Telephone: (212) 218-2100

Facsimile: (212) 218-2200

Respectfully submitted,

Dated: March 24, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100



#### **CERTIFICATE OF SERVICE**

I certify that a copy of Patent Owner's Mandatory Notices Under 37 C.F.R. § 42.8(a)(2) was served on March 24, 2017 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Keith A. Zullow (kzullow@goodwinprocter.com)

Marta E. Delsignore (mdelsignore@goodwinprocter.com)

Dated: March 24, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

